List of Excipients in Branded Drug SUTENT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	SUTENT	sunitinib malate	0069-0550	CROSCARMELLOSE SODIUM
Pfizer Laboratories Div Pfizer Inc	SUTENT	sunitinib malate	0069-0550	FERRIC OXIDE RED
Pfizer Laboratories Div Pfizer Inc	SUTENT	sunitinib malate	0069-0550	GELATIN

SUTENT Excipient Strategy and Commercial Opportunities for Sunitinib Capsules

Last updated: August 2, 2026

SUTENT is an oral sunitinib malate capsule marketed by Pfizer for gastrointestinal stromal tumor, advanced renal cell carcinoma, and pancreatic neuroendocrine tumors. Its formulation uses conventional, widely available excipients: mannitol, croscarmellose sodium, povidone, magnesium stearate, and hard-gelatin capsule components.[1] The core commercial opportunity is therefore not a novel excipient patent position. It is reliable supply, generic-scale manufacturing, capsule-shell differentiation, formulation robustness, and regional regulatory execution.

Sunitinib is no longer protected by primary U.S. compound exclusivity. Generic entry has materially reduced originator revenue, but the product remains commercially relevant because it is a chronic oral oncology therapy with established clinical demand, multiple dosage strengths, and potential for supply contracts in emerging markets.

What excipients are used in SUTENT capsules?

SUTENT capsules use a conventional immediate-release solid oral formulation.

Component	Function in the formulation	Commercial relevance
Sunitinib malate	Active pharmaceutical ingredient	Requires control of polymorphic, particle-size, assay, and impurity attributes
Mannitol	Diluent and bulking agent	Supports capsule fill weight and powder handling
Croscarmellose sodium	Disintegrant	Promotes rapid capsule-content dispersion
Povidone	Binder and processing aid	Supports granule or powder cohesion
Magnesium stearate	Lubricant	Reduces tooling and capsule-fill friction
Hard-gelatin capsule	Dosage-form shell	Provides the principal route for shell-material and color differentiation
Titanium dioxide, iron oxides, and printing components	Color and identification system	Relevant to visual differentiation, supply, and regional formulation changes

The precise excipient quantities and capsule colors are controlled by the approved product information and manufacturing specifications. The U.S. prescribing information identifies mannitol, croscarmellose sodium, povidone, and magnesium stearate as inactive ingredients.[1]

The formulation is commercially attractive for generic development because it does not depend on a complex delivery system, lipid carrier, modified-release matrix, or device. A manufacturer can pursue a conventional hard-capsule product, subject to pharmaceutical equivalence, bioequivalence, stability, and quality requirements.

Why is SUTENT’s excipient profile commercially important?

The excipient profile creates a relatively low technical barrier but a meaningful execution barrier.

Mannitol and croscarmellose sodium are commonly available from multiple qualified suppliers. Povidone and magnesium stearate also have broad supplier bases. This reduces dependence on one proprietary excipient platform. The main development risks are powder-flow variability, blend uniformity at low drug loading, lubricant sensitivity, capsule-fill consistency, and dissolution performance.

Sunitinib capsules are available in several strengths, including 12.5 mg, 25 mg, 37.5 mg, and 50 mg.[1] A manufacturer must maintain dose proportionality and consistent in vitro performance across strengths. The 12.5 mg strength can present greater content-uniformity risk because the active represents a smaller fraction of the total fill.

A generic developer can obtain commercial value through:

• dual-source qualification for mannitol, croscarmellose sodium, povidone, and magnesium stearate;
• capsule-shell sourcing from more than one manufacturer;
• gelatin-free or reduced-animal-origin capsule alternatives where accepted by regulators;
• colorant-free or simplified-color capsule designs;
• improved powder-flow and automated filling performance;
• lower-cost regional packaging and serialization;
• contract manufacturing for markets where Pfizer supply is limited;
• specialty distribution for oncology and hospital channels.

These strategies do not necessarily create patent exclusivity. They can improve gross margin, supply resilience, and regulatory flexibility.

What formulation attributes must a generic SUTENT developer match?

A generic sunitinib capsule must match the reference product’s critical quality attributes rather than merely reproduce its inactive-ingredient list.

Content uniformity

Sunitinib malate must be uniformly distributed through the capsule fill. This is especially important for the 12.5 mg and 25 mg presentations. Blend segregation, electrostatic behavior, and differences in particle size between the active and mannitol can affect dose consistency.

Dissolution

Croscarmellose sodium level, povidone concentration, magnesium stearate mixing time, and active-particle properties can alter dissolution. Excessive lubrication can slow wetting and dissolution. The developer must control lubricant addition and blending time.

Powder flow

Mannitol grade, particle morphology, and moisture content influence flow through capsule-filling equipment. Povidone can improve cohesion but may increase agglomeration if the formulation is overbound.

Stability

The finished product must control moisture exposure, capsule-shell brittleness, assay, degradation products, and dissolution over shelf life. Packaging selection, including high-barrier bottles or blister systems, can become a commercial differentiator in humid markets.

Capsule identification

Color and imprinting support strength differentiation and medication safety. A generic manufacturer can change the shell appearance, but the design must remain clearly distinguishable and meet labeling and product-identification requirements.

What patents protect SUTENT and its formulation?

SUTENT’s historic U.S. patent estate centered primarily on sunitinib chemistry and therapeutic uses rather than a highly differentiated excipient system.

IP category	Representative protection	Commercial implication
Compound patent	U.S. Patent No. 6,573,293	Covered the sunitinib chemical entity and was central to early market exclusivity
Therapeutic-use patents	U.S. Patent No. 7,125,905 and related rights	Addressed selected oncology uses and affected generic launch planning
Formulation protection	No widely recognized market-blocking SUTENT excipient platform	Conventional excipient substitution is commercially possible if regulatory requirements are met
Regulatory exclusivity	New-drug and orphan-related exclusivities applied at different times	Historical barriers have expired or been overtaken by generic entry

The U.S. Orange Book remains the controlling source for current patent listings and expiration information.[2] Patent status must be evaluated by product, indication, dosage form, and jurisdiction. A patent covering a method of treating one cancer indication does not necessarily block an ANDA for all labeled uses if appropriate labeling restrictions are available.

The main practical point for excipient developers is that SUTENT does not appear to depend on a commercially dominant, proprietary excipient combination. A formulation-only strategy is more likely to support manufacturing efficiency or product differentiation than to create a long period of enforceable exclusivity.

When did SUTENT lose exclusivity and when did generic entry begin?

SUTENT received U.S. approval in 2006 for advanced renal cell carcinoma and imatinib-resistant or imatinib-intolerant gastrointestinal stromal tumor. The pancreatic neuroendocrine tumor indication followed in 2011.[1]

The principal U.S. compound patent expired in the early 2020s, with patent-term adjustments and pediatric considerations affecting the precise timing of generic availability. FDA-approved generic sunitinib products entered the U.S. market after the principal exclusivity period ended.[2][3]

Milestone	Timing
Initial FDA approval for SUTENT	2006
pNET indication added	2011
Principal compound protection	Expired in the early 2020s
U.S. generic approvals	Began after primary exclusivity ended
Current market structure	Pfizer originator plus multiple generic suppliers

The commercial consequence was rapid erosion in originator share rather than disappearance of demand. Sunitinib remains an established oral oncology product with recognized dosing, monitoring, and procurement pathways.

What was the impact of SUTENT generic entry on Pfizer revenue?

SUTENT revenue declined materially before and after generic competition. Pfizer reported SUTENT revenue of roughly $1 billion annually around the earlier part of the product’s mature lifecycle, followed by substantial erosion as competition developed and generic products entered.[4]

The revenue exposure is concentrated in three areas:

1. U.S. and Western European originator share.
2. Reimbursement-driven substitution in oncology channels.
3. Price compression in tenders and institutional procurement.

Generic entry does not eliminate commercial opportunities. It shifts value from originator pricing to manufacturing scale, regulatory approvals, dependable supply, and market access. A supplier with low-cost, validated excipient sourcing can compete more effectively where distributors and hospitals prioritize continuity and price.

What generic entry risks exist for SUTENT?

Generic entry risk is high in markets where patent protection has expired and the product is regulated through an ANDA or equivalent pathway.

The principal risks are:

• abbreviated approval by multiple generic manufacturers;
• substitution at the pharmacy or hospital level;
• lower reimbursement ceilings;
• tender-based price competition;
• parallel trade between European markets;
• shortage-driven regulatory scrutiny;
• difficulty differentiating a conventional immediate-release capsule;
• indication-specific labeling constraints arising from method-of-use patents.

A Paragraph IV certification would be relevant when an ANDA applicant alleges that an Orange Book-listed patent is invalid, unenforceable, or not infringed. SUTENT’s key Paragraph IV exposure was tied to the compound and use-patent estate, not to a distinctive excipient technology.[2][3]

What formulation opportunities exist for SUTENT generics?

Capsule-shell substitution

A developer may evaluate hard-gelatin, hypromellose, or other capsule-shell systems. The business case includes vegetarian positioning, reduced animal-origin exposure, and alternative shell sourcing. The change can affect moisture permeability, shell mechanics, dissolution, and stability.

Colorant reduction

A simpler capsule-color system can reduce dependence on iron oxides or titanium dioxide and lower the risk of colorant supply disruption. The product must remain visually distinguishable by strength and comply with local excipient rules.

Manufacturing-process optimization

The most credible near-term opportunity is process improvement. Direct capsule filling, dry blending, roller compaction, or limited granulation may be assessed depending on powder behavior. The chosen process must preserve content uniformity and dissolution.

Packaging improvements

High-barrier blister packs can improve protection in hot and humid markets. Unit-dose hospital packaging can reduce dispensing errors and support oncology-clinic workflows.

Pediatric and low-dose presentations

Sunitinib has established adult capsule strengths, but lower-dose or flexible-dose presentations could support dose titration where medically appropriate. A new dosage form would require a separate regulatory strategy and would face greater clinical, stability, and bioequivalence requirements than a standard generic capsule.

Supply-chain resilience

Dual sourcing of excipients and capsule shells is a practical opportunity. Suppliers that provide compendial-grade material, documented change control, low endotoxin or bioburden profiles where relevant, and reliable regional inventory can gain value even without owning formulation patents.

How strong is the SUTENT patent estate for an excipient supplier?

The patent estate is weak as a direct barrier to conventional excipient supply. A supplier selling mannitol, croscarmellose sodium, povidone, magnesium stearate, or capsule shells is unlikely to be blocked solely because the materials are used in a sunitinib capsule.

The stronger legal risks are downstream:

• a finished-dose product may infringe a live formulation patent if one is listed or otherwise enforceable;
• a generic label may implicate a method-of-use patent;
• a manufacturing process may be covered in a jurisdiction-specific patent;
• a supplier may be contractually restricted by a customer’s quality or exclusivity agreement;
• an excipient change may trigger regulatory bridging requirements.

The appropriate commercial strategy is freedom-to-operate review at the finished-product and process levels, not reliance on excipient commoditization alone.

Which companies are challenging or competing with SUTENT?

Competition comes from two groups.

Generic sunitinib manufacturers

FDA-approved generic suppliers and authorized distributors compete through ANDA approvals, price, channel coverage, and supply reliability. The market can change as additional manufacturers obtain approval or withdraw products.

Therapeutic alternatives

SUTENT competes clinically with other renal-cell-carcinoma and gastrointestinal-stromal-tumor therapies, including pazopanib, axitinib, cabozantinib, imatinib in relevant GIST settings, and immune-checkpoint-based regimens. These products do not directly compete as excipient substitutes, but they reduce the addressable market for sunitinib in treatment algorithms.

For excipient companies, the relevant opportunity is greater in volume-driven generic supply than in originator reformulation.

What FDA regulatory status applies to SUTENT and generic sunitinib?

SUTENT is an FDA-approved prescription capsule. Generic versions are generally approved through the ANDA pathway, which requires pharmaceutical equivalence and bioequivalence to the reference listed drug.[1][3]

A generic developer must address:

• same active ingredient, strength, dosage form, and route;
• bioequivalence;
• inactive-ingredient suitability;
• dissolution and stability;
• manufacturing controls;
• labeling and product identification;
• patent certifications under the Hatch-Waxman framework;
• risk management and oncology labeling requirements.

A materially different formulation, new dosage form, or novel delivery system may require a more extensive 505(b)(2) strategy rather than a conventional ANDA.

What licensing opportunities exist around SUTENT excipients?

Direct licensing of Pfizer’s SUTENT excipient composition is unlikely to be the main opportunity because the formulation uses standard excipients and the product is mature.

More realistic commercial structures include:

• supply agreements with generic manufacturers;
• preferred-vendor contracts for capsule shells;
• regional distribution licenses;
• contract development and manufacturing agreements;
• technology-transfer arrangements for high-throughput capsule filling;
• co-development of gelatin-free or colorant-reduced versions;
• packaging and serialization contracts;
• formulation-support agreements tied to bioequivalence and scale-up.

The strongest value proposition is operational: validated supply, lower total manufacturing cost, documented quality, and rapid support for post-approval changes.

How does SUTENT compare with other oral oncology capsules?

Product	Dosage form	Excipient opportunity	Patent and market profile
SUTENT, sunitinib	Immediate-release hard capsule	Conventional excipient and shell optimization	Mature product with generic competition
VOTRIENT, pazopanib	Tablet	More complex tablet formulation and solid-state controls	Generic and patent analysis differs by jurisdiction
INLYTA, axitinib	Tablet	Tablet compression, dissolution, and stability	Smaller product with distinct compound and use patents
GLEEVEC, imatinib	Tablet/capsule depending on market	Broad generic manufacturing base	Long-established generic competition
CABOMETYX, cabozantinib	Tablet	More active patent and regulatory barriers in many markets	Later-generation product with higher exclusivity exposure

SUTENT is comparatively accessible for generic formulation development because its dosage form is a conventional capsule and its listed excipients are widely used. Its commercial disadvantage is limited product differentiation after generic entry.

Key Takeaways

• SUTENT contains sunitinib malate with mannitol, croscarmellose sodium, povidone, magnesium stearate, and hard-gelatin capsule components.
• The formulation has low excipient complexity and no obvious proprietary delivery platform.
• The primary commercial opportunity is generic manufacturing, not licensing a novel SUTENT excipient technology.
• Capsule-shell substitution, colorant reduction, packaging, powder-flow control, and dual sourcing are practical opportunities.
• The principal legal risks arise from compound, method-of-use, formulation, and process patents at the finished-product level.
• U.S. compound exclusivity has ended, and generic sunitinib competition has materially reduced Pfizer’s revenue.
• Excipient suppliers can capture value through supply reliability, regulatory documentation, manufacturing support, and cost control.

FAQs About SUTENT Excipients and Commercial Opportunities

Can a generic manufacturer change the excipients in SUTENT capsules?

Yes. A generic manufacturer may use different inactive ingredients if the product remains pharmaceutically equivalent, bioequivalent, stable, and acceptable under FDA requirements.

Is mannitol in SUTENT protected by a patent?

Mannitol itself is a widely used pharmaceutical excipient and is not proprietary to SUTENT. Any relevant risk would arise from a specific finished formulation, manufacturing process, or use claim.

Are SUTENT capsules suitable for a 505(b)(2) reformulation?

A conventional equivalent capsule is generally suited to an ANDA strategy. A substantially different dosage form, delivery system, or clinical-use proposition may require a 505(b)(2) pathway.

What is the best excipient opportunity in generic sunitinib?

The strongest opportunity is a validated, cost-efficient supply platform covering mannitol, croscarmellose sodium, povidone, magnesium stearate, and capsule shells, supported by dual sourcing and documented change control.

Does SUTENT have biosimilar risk?

No. Sunitinib is a small-molecule drug, not a biologic. Its competitive risk is generic substitution, not biosimilar interchangeability.

References

1. U.S. Food and Drug Administration. (2024). SUTENT (sunitinib malate) capsules: Prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: SUTENT and approved abbreviated new drug applications. U.S. Department of Health and Human Services.

4. Pfizer Inc. (2024). Annual report 2023. Pfizer Inc.